Top 5 Most-Read Ovarian Cancer Content of 2024

This year's top 5 ovarian cancer articles covered various topics, including the impact of air pollution on ovarian cancer risk, treatment strategies for patients with liver metastases, and the benefits of early diagnosis through symptom-triggered testing.

Here are our 5 most-viewed ovarian cancer pieces of 2024.

5. Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases

This May article reported that researchers considered chemotherapy and surgery as the only protective factors for overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer. The prognostic implications of therapies in this population were previously unknown, so investigators analyzed the respective morbidity and mortality trends. After adjusting for all covariates, OS and CSS were associated with patients with ovarian cancer and liver metastases who received surgery and/or chemotherapy. This provides guidance for selecting optimal treatment modalities to improve prognosis in this population.

Read the full article.

4. Age, Tumor Metastasis, Surgical Treatment Contribute to Cardiovascular Mortality in Patients With Ovarian Cancer

Age, surgical treatment, and tumor metastasis are independent prognostic factors for cardiovascular mortality (CVM) in patients with ovarian cancer, according to findings summarized in a May article. While previous research established a higher CVM risk among patients with cancer, specific predictors for CVM in patients with ovarian cancer had not been identified. However, a recent study observed that more than half of patients with ovarian cancer aged over 60 suffer from CVM, while those who underwent surgery faced a lower risk. Also, OS significantly improved in patients whose tumors did not develop distant metastasis. The researchers highlighted the need for further research into additional risk factors to refine treatment and surveillance strategies.

Read the full article.

3. Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases

This April article reported a downward trend in morbidity and mortality rates among patients with liver metastases from ovarian cancer, the most common site of distant metastasis. Among this population, investigators examined trends in morbidity, mortality, and the impact of different treatments on their OS and CSS. They found a significant decreasing trend in the incidence rate of liver metastases in patients with ovarian cancer, as well as in all-cause and cancer-specific mortality. More specifically, receiving surgery and/or chemotherapy was associated with OS and CSS.

Read the full article.

2. Increased Ovarian Cancer Risk Linked to Elevated Nitrogen Dioxide Exposure, Study Finds

Greater ambient nitrogen dioxide (NO₂) exposure may be associated with higher ovarian cancer incidence, according to findings covered in an October article. The researchers investigated the relationship between individual-level residential estimates of air pollution (NO₂, PM_2.5, and ozone [O₃]) and incident ovarian cancer, expanding on past research that identified a positive association between county-level ambient particulate matter (PM_2.5) exposure and ovarian cancer incidence. They found that a 5 parts per billion (PPB) increase in NO₂ was associated with a higher incidence of ovarian cancer. Additionally, they observed that exposure to O₃ and PM_2.5 was linked to ovarian cancer incidence only during premenopausal years.

Read the full article.

1. Symptom-Triggered Testing Detects Early-Stage Ovarian Cancer in 1 in 4 Women

This August article covered study findings that 1 in 4 women diagnosed with high-grade serous ovarian cancer through symptom-triggered testing, or the “fast-track pathway,” was found to have early-stage disease. The researchers analyzed data from the Refining Ovarian Cancer Test Accuracy Scores (ROCKeTS) study, revealing that 25.2% of patients diagnosed via the fast-track pathway had stage I/II disease, and 61.3% achieved complete cytoreduction. Despite their limitations, these findings suggest that symptom-based testing could improve early detection and survival outcomes among patients with high-grade serous ovarian cancer.

Read the full article.